VBI Vaccines to Participate in Upcoming Investor Conferences
November 14 2022 - 08:00AM
Business Wire
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical
company driven by immunology in the pursuit of powerful prevention
and treatment of disease, today announced that members of the
management team will participate in analyst-led fireside chats at
the following investor conferences:
Guggenheim’s 4th Annual Immunology and Neurology Day
Date: Tuesday, November 15, 2022 Time: 3:20-3:45PM
ET Presenter: Christopher McNulty, CFO & Head of
Business Development
Jefferies London Healthcare Conference
Date: Wednesday, November 16, 2022 Time:
8:00-8:30AM GMT Presenter: Jeff Baxter, President &
CEO
Live webcasts of the presentations will be available on the
Investors page of VBI’s website at:
https://www.vbivaccines.com/investors/events-and-presentations/. A
replay of the webcast will be archived on the Company’s website
following the presentation.
About VBI Vaccines Inc. VBI Vaccines Inc. (“VBI”) is a
biopharmaceutical company driven by immunology in the pursuit of
powerful prevention and treatment of disease. Through its
innovative approach to virus-like particles (“VLPs”), including a
proprietary enveloped VLP (“eVLP”) platform technology, VBI
develops vaccine candidates that mimic the natural presentation of
viruses, designed to elicit the innate power of the human immune
system. VBI is committed to targeting and overcoming significant
infectious diseases, including hepatitis B, coronaviruses, and
cytomegalovirus (CMV), as well as aggressive cancers including
glioblastoma (GBM). VBI is headquartered in Cambridge,
Massachusetts, with research operations in Ottawa, Canada, and a
research and manufacturing site in Rehovot, Israel. For more
information, visit www.vbivaccines.com.
Cautionary Statement on Forward-looking Information
Certain statements in this press release that are forward-looking
and not statements of historical fact are forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995 and are
forward-looking information within the meaning of Canadian
securities laws (collectively, “forward-looking statements”). The
Company cautions that such statements involve risks and
uncertainties that may materially affect the Company’s results of
operations. Such forward-looking statements are based on the
beliefs of management as well as assumptions made by and
information currently available to management. Actual results could
differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including but not
limited to, the impact of general economic, industry or political
conditions in the United States or internationally; the impact of
the ongoing COVID-19 pandemic and the ongoing effects of the
COVID-19 pandemic on our clinical studies, manufacturing, business
plan, and the global economy; the ability to successfully
manufacture and commercialize PreHevbrio/PreHevbri; the ability to
establish that potential products are efficacious or safe in
preclinical or clinical trials; the ability to establish or
maintain collaborations on the development of pipeline candidates
and the commercialization of PreHevbrio/PreHevbri; the ability to
obtain appropriate or necessary regulatory approvals to market
potential products; the ability to obtain future funding for
developmental products and working capital and to obtain such
funding on commercially reasonable terms; the Company’s ability to
manufacture product candidates on a commercial scale or in
collaborations with third parties; changes in the size and nature
of competitors; the ability to retain key executives and
scientists; and the ability to secure and enforce legal rights
related to the Company’s products. A discussion of these and other
factors, including risks and uncertainties with respect to the
Company, is set forth in the Company’s filings with the SEC and the
Canadian securities authorities, including its Annual Report on
Form 10-K filed with the SEC on March 7, 2022, and filed with the
Canadian security authorities at sedar.com on March 7, 2022, as may
be supplemented or amended by the Company’s Quarterly Reports on
Form 10-Q. Given these risks, uncertainties and factors, you are
cautioned not to place undue reliance on such forward-looking
statements, which are qualified in their entirety by this
cautionary statement. All such forward-looking statements made
herein are based on our current expectations and we undertake no
duty or obligation to update or revise any forward-looking
statements for any reason, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221114005275/en/
VBI Contact Nicole Anderson Director, Corporate
Communications & IR Phone: (617) 830-3031 x124 Email:
IR@vbivaccines.com
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From May 2023 to Jun 2023
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Jun 2022 to Jun 2023